BioLineRx Ltd. [NASDAQ: BLRX] closed the trading session at $2.67 on 12/11/20. The day’s price range saw the stock hit a low of $2.4307, while the highest price level was $2.70. The company report on November 23, 2020 that BioLineRx Ltd. to Host Earnings Call.
BioLineRx Ltd. (NASDAQ:BLRX) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on November 23, 2020 at 10:00 AM Eastern Time.
To listen to the event live or access a replay of the call – visit https://www.investornetwork.com/event/presentation/71815.
The stocks have a year to date performance of 18.67 percent and weekly performance of 15.09 percent. The stock has been moved at 64.81 percent over the last six months. The stock has performed 12.18 percent around the most recent 30 days and changed 54.34 percent over the most recent 3-months.
If compared to the average trading volume of 4.99M shares, BLRX reached to a volume of 1744449 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about BioLineRx Ltd. [BLRX]:
Maxim Group have made an estimate for BioLineRx Ltd. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 18, 2017. While these analysts kept the previous recommendation, Rodman & Renshaw raised their target price to Buy. The new note on the price target was released on February 13, 2017, representing the official price target for BioLineRx Ltd. stock. Previously, the target price had yet another drop from $4 to $1, while Maxim Group kept a Hold rating on BLRX stock. On August 17, 2015, analysts decreased their price target for BLRX shares from 8 to 4.
The Average True Range (ATR) for BioLineRx Ltd. is set at 0.23 The Price to Book ratio for the last quarter was 2.12.
BLRX stock trade performance evaluation
BioLineRx Ltd. [BLRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 15.09. With this latest performance, BLRX shares gained by 12.18% in over the last four-week period, additionally plugging by 64.81% over the last 6 months – not to mention a rise of 1.52% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BLRX stock in for the last two-week period is set at 65.81, with the RSI for the last a single of trading hit 70.19, and the three-weeks RSI is set at 63.20 for BioLineRx Ltd. [BLRX]. The present Moving Average for the last 50 days of trading for this stock 2.05, while it was recorded at 2.46 for the last single week of trading, and 1.82 for the last 200 days.
BioLineRx Ltd. [BLRX]: An insightful look at the core fundamentals
Return on Total Capital for BLRX is now -59.19, given the latest momentum, and Return on Invested Capital for the company is -55.78. Return on Equity for this stock declined to -67.23, with Return on Assets sitting at -45.89. When it comes to the capital structure of this company, BioLineRx Ltd. [BLRX] has a Total Debt to Total Equity ratio set at 31.32. Additionally, BLRX Total Debt to Total Capital is recorded at 23.85, with Total Debt to Total Assets ending up at 19.52. Long-Term Debt to Equity for the company is recorded at 22.65, with the Long-Term Debt to Total Capital now at 17.25.
Reflecting on the efficiency of the workforce at the company, BioLineRx Ltd. [BLRX] managed to generate an average of -$2,158,673 per employee.
Earnings per share (EPS) analysis for BioLineRx Ltd. [BLRX] stock
With the latest financial reports released by the company, BioLineRx Ltd. posted -0.9/share EPS, while the average EPS was predicted by analysts to be reported at -0.66/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -36.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BLRX.
BioLineRx Ltd. [BLRX]: Insider Ownership positions
Positions in BioLineRx Ltd. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 8 institutional holders increased their position in BioLineRx Ltd. [NASDAQ:BLRX] by around 1,042,170 shares. Additionally, 5 investors decreased positions by around 156,296 shares, while 8 investors held positions by with 2,857,334 shares. The mentioned changes placed institutional holdings at 4,055,800 shares, according to the latest SEC report filing. BLRX stock had 4 new institutional investments in for a total of 715,824 shares, while 2 institutional investors sold positions of 19,339 shares during the same period.